Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
Study Details
Study Description
Brief Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving rituximab together with vaccine therapy and GM-CSF may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with vaccine therapy and GM-CSF works in treating patients with indolent B-cell non-Hodgkin's lymphoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
OBJECTIVES:
-
Determine the efficacy of immunotherapy comprising rituximab, autologous immunoglobulin idiotype-KLH conjugate vaccine (FavId™), and sargramostim (GM-CSF), in terms of response rate (partial and complete) and event-free survival, in patients with indolent B-cell non-Hodgkin's lymphoma.
-
Determine the safety of this regimen in these patients.
-
Evaluate development of an immune response in patients treated with this regimen.
OUTLINE: This is an open-label, multicenter study.
-
Induction therapy: Patients receive rituximab IV over 2-4 hours once weekly for 4 weeks. Patients are evaluated for response at month 3. Patients with responding or stable disease proceed to maintenance therapy. Patients with progressive disease are removed from study.
-
Maintenance therapy: Patients receive rituximab as in induction therapy in months 7, 13, and 19. Patients also receive autologous immunoglobulin idiotype-KLH conjugate vaccine (FavId™) subcutaneously (SC) once on day 1 and sargramostim (GM-CSF) SC once daily on days 1-4 in months 4-6, 8-11, 14, 16, 18, 20, 22, and 24. Patients with continued response after completing 2 years of therapy may continue to receive FavId™ and GM-CSF once every 3 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 56 patients will be accrued for this study.
Study Design
Outcome Measures
Primary Outcome Measures
- Event-free survival by Kaplan-Meier []
Secondary Outcome Measures
- Overall response rate (partial and complete response) at month 6 and any time []
- Time-to-progression by Kaplan-Meier []
- Duration of response []
- Immune response by cellular or humoral anti-idiotype response positive []
- Safety []
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Histologically confirmed indolent B-cell non-Hodgkin's lymphoma of 1 of the following subtypes:
-
Grade 1 or 2 follicular lymphoma
-
Tumor must be accessible to biopsy or biopsy material available for preparation of autologous immunoglobulin idiotype-KLH conjugate vaccine (FavId™)
-
Measurable or evaluable disease after node biopsy
-
No mantle cell, marginal zone, MALT-type, small lymphocytic, or grade 3 follicular (follicular large cell) lymphoma
-
No CNS involvement with lymphoma
PATIENT CHARACTERISTICS:
Performance status
- ECOG 0-2
Life expectancy
- Not specified
Hematopoietic
-
Platelet count > 100,000/mm^3
-
WBC ≥ 3,000/mm^3
Hepatic
-
AST and ALT ≤ 2 times upper limit of normal
-
Bilirubin ≤ 2 mg/dL
Renal
- Creatinine ≤ 1.5 mg/dL
Other
-
Not pregnant or nursing
-
Negative pregnancy test
-
Fertile patients must use effective contraception during and for 30 days after completion of study treatment
-
HIV negative
-
No other medical or psychiatric disease that would preclude study compliance
-
No other malignancy (active or treated) within the past 5 years
PRIOR CONCURRENT THERAPY:
Radiotherapy
- Prior local radiotherapy allowed
Other
- No other prior anticancer therapy
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Sarah Cannon Cancer Center at Centennial Medical Center | Nashville | Tennessee | United States | 37203 |
Sponsors and Collaborators
- Favrille
Investigators
- Study Chair: John F. Bender, PharmD, Favrille
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CDR0000449719
- FAV-ID-70
- FAV-ID-LYM-31